|
1. Biologie
|
|
|
|
|
|
|
2.6 Etiologie - Environnement
|
|
|
|
3. Prévention
|
|
|
Curcumin Will Waste Your Time [In the Pipeline]
|
|
|
|
|
|
In
cell, tissue, and animal assays, it falls into the category of
“Invalid/Improbable Metabolic Panacea” (IMP), a term that’s been used
for natural products that seem to have all sorts of weakish activity all
over the place. Unfortunately, the literature is full of reports of
curcuminoid compounds as actives for all sorts of specific molecular
targets (this latest review goes into several of these).
|
|
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
Welsh government to introduce improved screening tests for cervical and bowel cancers [Cancer Research UK]
|
|
|
|
|
|
From
April 2017 a pilot programme will switch the order of the tests used
for cervical screening. This will see the test that detects high risk
forms of human papillomavirus (HPV) infection, which is the main cause
of cervical cancer, offered first. A full roll-out is expected to start
in 2018/19. For bowel cancer, the faecal Immunochemical test (FIT),
which can be more accurate than the current test, will be introduced
during 2018/19.
|
|
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5. Traitements
|
|
|
|
5.10 Traitements - Essais
|
|
|
NCI Launches Formulary to Speed Availability of Investigational Cancer Drugs [RAPS]
|
|
|
|
|
|
Specifically,
NCI says its Cancer Therapy Evaluation Program (CTEP) will act as an
intermediary between investigators and participating drugmakers to
negotiate agreements to allow the use of specific agents in
NCI-supported studies, including preclinical and clinical studies
conducted under an investigational new drug (IND) application.
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
5.12.3 Immunothérapies-combinaisons
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.2.3 Pharma - économie
|
|
|
|
It’s the Drug Industry’s Turn to Tremble Before Trump [Bloomberg]
|
|
|
|
|
|
The
uncertainty Trump has thrown into the sector has ground some strategic
plans to a halt. There’s a sense among investors that until policies are
settled that will affect tax rates, government payments and how health
markets are organized, little can happen in the industry.
|
|
|
|
|
5.3 Traitements - FDA, EMA, NICE...
|
|
|
Multiple Endpoints in Clinical Trials: FDA Issues Draft Guidance [RAPS]
|
|
|
|
|
|
“The
purpose of this guidance is to describe various strategies for grouping
and ordering endpoints for analysis and applying some well-recognized
statistical methods for managing multiplicity within a study in order to
control the chance of making erroneous conclusions about a drug’s
effects.”
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.6 Publications
|
|
|
|
6.9 Controverses
|
|
|
|
|
|